Table 1

Number of drug target genes identified using disease associations interacting with CHi-C genes for each disease and the corresponding number of drugs

DiseaseGenes identified by CHi-C (n)Genes which are existing drug targets (n)Drugs identified (n)Drugs currently used (n)Drugs for potential repositioning (n)
  • Among the drugs currently in use, six effective biologic therapies (adalimumab, etanercept and rituximab (FCGR2A), sarilumab and tocilizumab (IL6R) and tofacitinib (TYK2)) were identified for RA, and a relatively recent treatment, apremilast (PDE4A), for PsA. Drugs with potential for repositioning included alemtuzumab (FCGR2A), natalizumab (ICAM1, FCGR2A) and daclizumab (IL2RA, FCGR2A).

  • CHi-C, Capture Hi-C; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.